1. The potential in esophageal cancer therapy
(1) The high EGFR expression in EC
• Over 50% of EC patients are found high EGFR expression in the tumor
• EGFR expression is highly correlated with the EC prognosis
(2) High Selectivity to EGFR Kinase
• Has a considerable inhibitory effect on the EGFR
(3) The Special in vivo distribution characteristics
• Distribute into esophagus tissues (T/B=61) and tumors (T/B=27.4)
2. Clinical Development Progress
(1) Esophageal Carcinoma (EC): Phase Ib/IIa trial finished. Phase III trial, ≥2L, has been started, with the first recruitment in November 2020.
(2) Pancreatic Cancer: Phase Ib trial started in Nov. 2019. NDA 2024.Q4
(3) ORR 20% (10/50) for the EC patients, with better efficacy than Pembrolizumab (ORR 16.7%).
ESCC (Esophageal Squamous Cell Carcinoma), ≥2L, Phase Ib/IIa, oral, RP2D 350 mg
3. Development Timeline
Expects to file the NDA in China for the first indication, esophageal cancer at the end of 2024 or at the beginning of 2025.
1. Asset type: EGFR inhibitor
2. Indication: Esophageal Carcinoma and Pancreatic Cancer
3. Target: EGFR / Her2 / Her4
4. Research phase: Phase III (Esophageal Carcinoma)\ Phase Ib (Pancreatic Cancer)
5. Cooperation demands: License-out or co-development for the global right and Clinical development in the US or EU (PK and Phase III)
6. Research progress:
(1) The asset expects to file the NDA in China for the first indication, esophageal cancer at the end of 2024 or at the beginning of 2025.
ComboX is a new brand of ACROBiosystems. ComboX products include our Streptavidin series products, coated plates, isotype controls for antibody and fusion protein drug research, and general-purpose antibodies.
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro is ACROBiosystems brand focused on neuroscience research, providing high-quality important proteins including therapeutic and diagnostic research proteins, PFFs and recombinant neuro factors, etc. to advance neuroscience research.
This web search service is supported by Google Inc.